AAL

Pfizer Gears up for Earnings Amid Vaccine News

Pfizer will report earnings before the open on Tuesday, Nov. 2

Deputy Editor
Oct 28, 2021 at 1:57 PM
facebook X logo linkedin


Pfizer Inc (NYSE:PFE) has hogged the spotlight lately, especially after a key U.S. Food and Drug Administration (FDA) panel endorsed the company's low-dose Covid-19 vaccine for children ages 5 to 11. Plus, Pfizer is gearing up for its third-quarter earnings report, due out before the open on Tuesday, Nov. 2. 

Ahead of these earnings, the options pits are pricing in a post-earnings swing of 4.5%, regardless of direction, which is higher than the average 2.5% move from the company's last eight earnings reports. Pfizer has a split history of post-earnings reactions, closing four of the last eight next-day sessions with gains -- including the two most recent reports. 

On the charts, PFE has been on the rise since bouncing off the $41 level and 160-day moving average in mid October, after steadily dropping from its August 18 record high of $51.86. Though the 40-day moving average has kept a cap on gains this week, the equity just broke past several short- and long-term moving averages above the $42 level, including the 10-day trendline.

There is plenty of room for bull notes that could send Pfizer stock higher. Of the 11 analysts in coverage, seven still carry a tepid "hold" rating on the pharmaceutical name. 

Pfizer 1028

  

 

Same-Day Trading Power: +227% YTD and Counting  — Get in for $10!

We're celebrating 44 years of helping traders win, and you can now tap into one of our most explosive services — Dynamite Day Trading Signals — for just $10.

This service was built for one thing: capturing intraday gains with precision. 

Access two highly-vetted options trades each week -  Complete with defined entries, exits, and a clear plan for same-day profits.

👉 Click Here to Learn More and Position Yourself to Take Action When the Next Alert Hits.